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Advisory Professor: David Rodriguez-Buritica, MD, FACMG 
 
 
 
Glycogen storage disease is a group of inborn errors of metabolism, with type Ia being 
the most common form of the disorder. Glycogen storage disease type Ia (GSDIa) is a 
multisystemic condition in which individuals have various complications secondary to an 
inability to properly break down glycogen and to perform gluconeogenesis. Complex 
management is then necessary for patients and includes dietary modification, frequent 
cornstarch usage, and evaluation for additional complications  such as hepatic adenomas, 
hypertriglyceridemia, and kidney disease . Previous studies have found lower scores in 
quality of life and body image in GSDIa patients; however, the specific factors 
influencing this relationship remain unknown. In this study, 24 adult participants (n=24) 
with glycogen storage disease type Ia completed a survey including measures of health-
related quality of life, body image, and metabolic control. Results found that quality of 
life was significantly lower than the general population on both the physical  and mental 
component scores (t=-3.11, p=0.005; t=-2.21, p=0.03). Additionally, body image was 
significantly lower on all subscales: Weight (t=-5.88, p<0.001), Appearance (t=-5.67, 
p<0.001), and Attribution (t=-2.38, p=0.02). In general, significance was not reached 
when examining roles that certain metabolic and demographic factors play in health-
related quality of life and body image. Therefore, the relationship between these factors 
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is most likely complex. Overall, the current study confirms previous fin dings of lower 
health-related quality of life and body image in this population and provides preliminary 
evidence on potential factors influencing this phenomenon.  
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INTRODUCTION 
The glycogen storage diseases are a group of disorders characterized by abnormalities in 
various enzymes that are involved in glycogen synthesis and/or degradation. Each subtype of 
glycogen storage disease have varying enzymatic deficiencies, in turn leading to varying phenotypic 
expression. Glycogen storage disease type Ia, also known as von Gierke disease, is due to deficiency 
of glucose-6-phosphotase (G6Pase) activity (Hendriksz & Gissen, 2015). G6Pase is expressed in the 
liver and is responsible for catalyzing final reactions of glycogenolysis and gluconeogenesis. The lack 
of activity of the G6Pase protein leads to a decrease in glucose output from the liver during fasting.  
Furthermore, the build-up of glucose-6-phosphate leads to increased G6P in glycolysis and increased 
lactate production. The gene that encodes G6Pase is called G6PC and is located on chromosome 
17q21 (Ozen, 2007; Wolfsdorf & Weinstein, 2003). GSDIa is inherited in an autosomal recessive 
manner; therefore, individuals with GSDIa have bi-allelic pathogenic variants in G6PC.  
Metabolic derangements of GSDIa include severe fasting hypoglycemia, lactic acidosis, 
hypertriglyceridemia and hyperuricemia. The clinical features of this condition are multisystemic and 
may include seizures, lethargy, and failure to thrive. In addition to low glucose levels, there is also 
buildup of glycogen in these patients, leading to hepatomegaly. Patients with GSDIa may exhibit 
short stature and characteristic facial features including a round “doll”-like face with full cheeks 
(Kishnani et al., 2014). Complications arise in the context of poor metabolic control and manifest as 
hepatic adenomas, renal disease, severe hypoglycemia potentially leading to brain damage, 
osteoporosis/osteopenia, and anemia (Kishnani et al., 2014). According to ACMG guidelines on 
management of GSD type I, care for these patients should occur in the context of a multidisciplinary 
team with expertise in glycogen storage disease (Kishnani et al., 2014). Various specialists should be 
involved, including nephrology, hepatology, hematology, genetics, and cardiology, in addition to 
metabolic disease specialists. Additionally, the specific diet required for these individuals is a lactose, 
galactose, sucrose, and fructose free diet. This is further managed through the use of frequent 
cornstarch dose given every 3 to 4 hours, during the day and at night, often times necessitating use of 
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a G-tube. Understandably this form of management then can have a significant impact on the daily 
routines of individuals with GSDIa.   
Researchers have suggested that further information on the relationship between metabolic 
control, body image, and quality of life would be useful to elucidate potential influencing factors of 
quality of life of patients with GSD (Flanagan et al., 2015). This research could provide insight for 
direction of adherence to diet and mental health care discussions for these patients. Because metabolic 
control as a factor influencing quality of life and body image in these patients has not been evaluated 
in depth before, the current study aims to further examine this question by eliciting information on the 
relationship between metabolic control, body image, and quality of life (QoL) in adult patients with 
glycogen storage disease type Ia. The authors hypothesize that individuals with better self-assessed 
and objective measures of metabolic control will have better quality of life and body esteem. 
 
METHODS 
Data was collected via a survey, using the system Qualtrics (Qualtric, Provo, UT) and 
consisting of four parts: demographics, metabolic control, quality of life, and body image.  
To evaluate for level of metabolic control, patients completed questions regarding amount of 
complications they report per week, what they are using for treatment of complications and 
hypoglycemia, and what their own perceived level of metabolic control was. Level of control in the 
study is defined as the degree to which individuals follow management and dietary guidelines. 
Participants were asked if they consider themselves to be under good metabolic control and to rate 
their level of metabolic control on a scale of 1 to 10, with 10 representing highest level of control. 
Participants were also asked about their frequency and dosage of cornstarch used and whether they 
take Glycosade™. The metabolic control section consisted of 21 questions in total. 
Short-Form 36 Version 2 (SF-36v2) Health Survey from OPTUM QualityMetric, Inc was 
used to measure Health-Related Quality of Life (HRQoL) in adult patients with GSDIa (Ware & 
Sherbourne, 1992). SF-36v2 is a 36 item validated and reliable measure of health-related quality of 
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life in the adult population. Subscales include physical functioning, role physical, bodily pain, general 
health perception vitality, social functioning, role emotional, and mental health. The mental 
component score (MCS) and physical component score (PCS), which are summary measures for 
mental and physical aspects of health-related quality of life, were used in analysis in the current 
study. Scores on the measure were standardized and converted to a 0-100 scale for analysis (Maruish; 
Ware & Sherbourne, 1992). 
Body image was measured using the Body Esteem Scale (Mendelson, Mendelson, & White, 
2001). The Body Esteem Scale is a validated measure analyzing level of satisfaction or dissatisfaction 
with one’s body and is comprised of three subscales. These subscales include Attribution, Weight, 
and Appearance. The Attribution subscale relates to the individuals perceptions on how others view 
their body. The Weight subscale represents their own perceptions about their weight and their 
satisfaction with their body. The Appearance subscale deals with how people perceive their own 
physical appearance and facial features. The scale consists of 30 items, answers for which take the 
format of a 5-point scale (0-4) (Mendelson et al., 2001). Of note, this measure was translated into 
Spanish by one of the researchers and the measure has not been previously validated in this language 
before. 
A link to the survey was posted to the Association of Glycogen Storage Disease US website 
(https://agsdus.org), Glucolatino listserv, and glycogen storage disease patient Facebook groups, and 
a recruitment flyer was sent via mail to patients currently enrolled in the GSD program at McGovern 
Medical School at UTHealth. The survey was available in both English and Spanish. Inclusion 
criteria for this study included any patient with a diagnosis of GSDIa who was over the age of 18, 
who clicked on the survey link and who consented to participate. Exclusion criteria included 
individuals who do not fall into the aforementioned categories or who do not have a diagnosis of 
GSDIa. Finally, the study was only available to individuals who speak either English or Spanish. 
Originally, parents of children with GSD type Ia and adolescents aged 13-17 with GSDIa were 
included in the study, however these groups were removed due to low sample size and response rate. 
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Overall, specific response rate was unable to be calculated due to a lack of information about how 
many individuals who fit the criteria saw the link to the survey, but did not choose to complete it. 
 Statistical analysis was completed using the software Stata (v13.1, College Station, TX, 
USA).  SF-36 and the Body Esteem Scale were scored using the recommended methods and 
compared to population norms (Maruish; Mendelson et al., 2001). Body image and QoL were 
compared to the US general population using one sample t-tests. Rank sum was used to evaluate sub-
groups due to the small sample size. Significance was assumed at a Type I error rate of 5%. 
 
RESULTS 
 Twenty-four adult patients with a diagnosis of GSDIa completed the survey. All surveys were 
fully completed except in one individual who did not complete the Body Esteem Scale (n = 23). The 
sample consisted of 5 male (21%) and 19 female participants and a majority identified as being 
Caucasian (88%, n=21) and from the United States (58%, n=14). Of individuals who reported being 
from the United States, the most commonly represented state was Texas (21%, n=3), followed by 
New York (14%, n=2). The age of participants ranged from 20-57 years old (median = 31). Three of 
the 24 participants (13%) completed the survey in Spanish. 
The median age of diagnosis for the sample was 0.5 years, with the range being from birth to 
20 years old. One could argue about verity of diagnosis for the individuals diagnosed at 20 years and 
19 years respectively due to the severity of the condition, however removal of these individuals from 
analysis did not significantly impact statistical results and therefore they were included. Average 
height of the sample was 158 cm with the average weight being 68.9 kg. One individual did not 
provide their weight and therefore sample size for weight and BMI are 23. Average BMI was 27.3 
kg/m2 (SD = 6) with 11 (48%) having a ‘healthy’ BMI (18.5-24.9 kg/m2) and 12 (52%) having a BMI 
classified as being overweight (>25 kg/m2).  No individuals had a BMI falling in the underweight 
category.  
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Table 1. Demographic characteristics   
    Count  Frequency (%) Mean (SD) Median (IQR) 
Gender     
 Male 5 20.8%   
 Female 19 79.2%   
Current Age   32.1 (9.1) 31 (25-38) 
Age of Diagnosis (years)  2.7 (5.4) 0.5 (0.3-1.8) 
Height (cm)   158.4 (7.7) 157.7 (153.2-164.1) 
Weight (kg) n = 23   68.9 (16.9) 70.3 (56.0-78.0) 
BMI n=23   27.3 (6.0) 25.8 (22.2-30.6) 
Race     
 Caucasian 21 87.5%   
 Asian 2 8.3%   
 Other 1 4.2%   
Ethnicity     
 Non-Hispanic 20 83.3%   
 Hispanic 4 16.7%   
Country     
 United States 14 58.3%   
 Mexico 2 8.3%   
 Canada 2 8.3%   
 Spain 1 4.2%   
 Germany 1 4.2%   
 Portugal 1 4.2%   
 Argentina 1 4.2%   
 Denmark 1 4.2%   
 Israel 1 4.2%   
State     
 Texas 3 21.4%   
 New York 2 14.3%   
 Michigan 1 7.1%   
 South Carolina 1 7.1%   
 Colorado 1 7.1%   
 New Jersey 1 7.1%   
 Illinois 1 7.1%   
 Wisconsin 1 7.1%   
 Illinois 1 7.1%   
 Virginia 1 7.1%   
  Alabama 1 7.1%     
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A majority of individuals reported checking their glucose at home (75%, n=18). Of those 
individuals, 56% (n=10) of them reported checking their glucose when they think that they are low, 
and 33% (n=6) checking multiple times a day. 11% (n=2) reported that they check their glucose once 
a day. Two individuals (8%) reported receiving tube feedings, with both individuals using g-tubes. 
Twenty individuals reported taking cornstarch (83%), with 18 providing some level of information on 
their cornstarch schedule. Of these 18, 10 individuals (55%) noted that they had sleep interrupted due 
to having to wake up to take cornstarch. Other reported medications used by the sample including 
25% (n=6) who take Glycosade™ and 50% (n=12) who take allopurinol. 
A majority of individuals reported having 1 to 5 low blood sugars a week (67%, n=16), with 
21% (n=5) being unsure how many they had. One individual each reported having no, 6 to 10, 
and >10 episodes of hypoglycemia a week. In terms of complications related to GSD 54% (n=13) of 
the sample reported having liver masses/hepatic adenomas, 25% (n=6) having osteoporosis, 46% 
(n=11) having kidney problems/kidney stones, 67% (n=16) having hypoglycemia every week at least 
once a week, and 92% (n=22) have high cholesterol or high triglycerides. Using those five 
complications listed, the mean number of complications for the sample was 2.8 with a standard 
deviation of 1.3.  
 Given scale of one to ten with ten being the highest control and one being the lowest, the 
mean self-perceived level of control for the sample was 5.9 with a standard deviation of 1.6. When 
looking at frequency of responses, no individuals reported scores of 1, 2, 9, and 10 (Figure 1). The 
most common reported score was 4 (26%). Additionally, 54% (n=13) consider themselves to be under 
good metabolic control (Table 2). 
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Table 2. Clinical characteristics and measures of control   
    Count  Frequency (%) Mean (SD) Median (IQR) 
Do you check your glucose at home? 18 75%   
Do you receive tube feedings?     
 No 22 91.7%   
 Yes 2 8.3%   
How often do you check your glucose?     
 Multiple times a day 6 33.3%   
 Once a day 2 11.1%   
 When I think I am low 10 55.6%   
How many LBS's do you have per week?     
 None 1 4.2%   
 1 to 5 16 66.7%   
 6 to 10 1 4.2%   
 >10 1 4.2%   
 Not sure 5 20.9%   
Complications reported     
 Liver masses/hepatic adenomas 13 54.2%   
 Osteoporosis 6 25.0%   
 Kidney problems/Kidney stones 11 45.8%   
 Low blood sugars every week 16 66.7%   
 High cholesterol or triglycerides 22 91.7%   
Number of complications (see above for list of   2.8 (1.3) 3 (2.0-3.5) 
complications)     
On a scale of 1 to 10 rate your level of    5.9 (1.6) 6.0 (4.0-7.0) 
metabolic control (10 being best control)     
Do you consider yourself to be under      
good metabolic control?     
 No 11 45.8%   
 Yes 13 54.2%   
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 Adult patients with glycogen storage disease type Ia were found to have lower health-related 
quality of life scores than the general population using the physical component score (PCS) (t=-3.11, 
p=0.005) and the mental component score (MCS) (t=-2.21, p=0.03) (Table 3). There was no 
statistically significant difference in quality of life found between males and females in both PCS 
(p=0.594) and MCS (p=0.414) (Table 4). 
In reference to body image, adult patients with GSDIa were found to have statistically 
significantly lower scores than the general population in all three subscales of body esteem: Weight 
(p<0.001), Appearance (p<0.001), and Attribution (p=0.02). (Table 3). When stratifying based on 
gender, females were found to be significantly lower than gender norms in Weight (p=0.002) and 
Appearance (p=0.005), but not Attribution (p=0.09). Similarly when comparing males in the sample 
to gender norms, they scored significantly lower in the Appearance subscale (p=0.04), but not the 
Weight (p=0.07) or Attribution subscale (p=0.12). 
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Figure 1. Scale of Control
Frequency of response regarding self-perceived level of control on a scale of 1 to 10, with 1 
representing poorest control and 10 representing best control. Most individuals fell in the 
middle values, with no responses falling in levels 1, 2, 9, or 10.   
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Table 3. QoL and body esteem compared to population controls   
Scales Count  Mean (SD) Median (IQR) t-score p-value 
SF-36 n=24     
 
Physical Component Score 
(PCS) 46.1 (8.6) 47.1 (41.9-51.9) -3.11 0.005 
 
Mental Component Score 
(MCS) 42.8 (11.3) 43.7 (35.3-51.1) -2.21 0.03 
Body Esteem Scale 
(BES) n=23     
 Weight  1.4 (0.9) 1.5 (0.6-1.8) -5.88 <0.001 
 Appearance  1.4 (1.0) 1.3 (0.6-2.2) -5.67 <0.001 
  Attribution   1.8 (0.9) 1.8 (1.0-2.3) -2.38 0.02 
 
When examining factors related to metabolic control and their influence on outcome 
measures including the MCS and PCS subscales of QoL, the Weight, Appearance, and Attribution 
subscales of the BES, and self-reported control on a scale of one to ten, a majority of factors were 
found to have no effect (Table 4). Men and women did not report significantly different scores in 
quality of life, body esteem, of scale of control. Checking glucose at home, taking cornstarch, taking 
Glycosade™, waking up at night, and receiving tube feedings were not significantly associated with 
scores on QoL, BES, or perceived metabolic control (Table 4). Individuals who considered 
themselves to be under good metabolic control reported significantly higher responses on scale of 
control (p<0.001). Taking allopurinol was significantly associated with scale of control, such that 
individuals who take allopurinol reported higher levels of self-perceived control (p=0.0155). 
Individuals taking allopurinol and/or Glycosade™ had higher control than those who took neither 
(p=0.009). However, there was no difference seen between individuals taking one or the other and 
those taking both (p=0.1255). Taking both allopurinol and Glycosade™ was also significantly 
associated with BMI, such that individuals who take both have on average higher BMI’s that 
individuals who take one or the other (p=0.009) and those who take neither (p=0.008). There was no 
difference in BMI seen between individuals who took neither allopurinol nor Glycosade™ and those 
who took one or the other (p=0.437). This relationship was also seen in reference to the Weight 
subscale of the BES. Individuals who took both Glycosade™ and allopurinol reported poorer scores 
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of the Weight subscale than individuals that took one or the other (p=0.014) and those who took 
neither (p=0.0497). 
Table 4. Potential factors influencing outcome measures     
Gender 
   Male (n=5)  Female (n=19) p-value 
   Mean (SD) Median (IQR)   Mean (SD) Median (IQR) 
MCS 40.5 (9.0) 42.7 (38.8-44.3)  43.4 (11.9) 44.3 (34.7-52.5) 0.594 
PCS 48.9 (12.1) 50.9 (42.1-55.5)  45.4 (7.7) 47.0 (41.9-50.7) 0.4136 
Weight 1.68 (1.26) 1.5 (0.89-2.25)  1.28 (0.86) 1.5 (0.36-1.75) 0.5673 
Appearance 1.36 (0.94) 1.3 (1.2-1.7)  1.38 (0.99) 0.90 (0.40-2.30) 1.00 
Attribution 1.8 (1.11) 1.6 (1-2)  1.74 (0.90) 1.80 (1.00-2.40) 0.7752 
Scale of control 7.0 (1.0) 7.0 (6.0-8.0)   5.6 (1.65) 5.5 (4.0-7.0) 0.0866 
        
Do you consider yourself to be under good metabolic control? 
   No (n=11)  Yes (n=13) p-value 
   Mean (SD) Median (IQR)   Mean (SD) Median (IQR) 
MCS 39.3 (12.4) 37.8 (26.1 - 51.9)  45.8 (9.8) 44.3 (38.8 - 50.4) 0.284 
PCS 45.9 (9.4) 47 (36.3 - 50.7)  46.3 (8.2) 48.1 (42.1 - 52.8) 0.728 
Weight 1 (0.7) 1.5 (0.1 - 1.5)  1.7 (1) 1.6 (0.9 - 2.3) 0.103 
Appearance 1.1 (0.9) 0.8 (0.4 - 2.1)  1.6 (1) 1.7 (0.9 - 2.3) 0.271 
Attribution 1.8 (0.6) 2 (1.6 - 2.2)  1.7 (1.1) 1.6 (1 - 2.6) 0.705 
Scale of control 4.5 (1.0) 4 (4 - 6)   7.1 (1) 7 (6.5 - 8) <0.001 
 
Do you check your glucose at home? 
   No (n=6)  Yes (n=18) p-value 
   Mean (SD) Median (IQR)   Mean (SD) Median (IQR) 
MCS 38.1 (14.5) 39.3 (24.8-50.3)  44.4 (10.0) 44.3 (37.7-51.9) 0.3173 
PCS 45 (8.5) 44.6 (41.9-50.9)  46.5 (8.8) 47.6 (42.1-52.9) 0.6407 
Weight 1.25 (1.13) 1.13 (0.25-1.75)  1.4 (0.90) 1.50 (0.88-1.75) 0.6388 
Appearance 0.9 (1.08) 0.60 (0.30-0.90)  1.53 (0.90) 1.50 (0.80-2.30) 0.1169 
Attribution 1.67 (0.98) 1.70 (1.00-2.60)  1.78 (0.98) 1.80 (1.20-2.20) 0.9466 
Scale of control 5.3 (1.97) 5.0 (4.0-7.0   6.1 (1.5) 6.0 (5.0-7.0) 0.3711 
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Do you take cornstarch? 
   No (n=4)  Yes (n=20) p-value 
   Mean (SD) Median (IQR)   Mean (SD) Median (IQR) 
MCS 37.6 (15.2) 37.7 (28.3-47.0)  43.9 (10.5) 44.3( 35.3-51.1) 0.4386 
PCS 38.8 (11.8) 33.5(31.8-45.7)  47.6 (7.3) 47.7 (42.5-51.9) 0.1213 
Weight 1.72 (1.23) 1.81(0.94-2.50)  1.29 (0.89) 1.50 (0.56-1.69) 0.2753 
Appearance 1.13 (1.27) 0.62 (0.32-1.95)  1.42 (0.92) 1.30 (0.75-2.20) 0.4614 
Attribution 1.55 (1.15) 1.70 (0.60-2.50)  1.79 (0.90) 1.80 (1.10-2.20) 0.8458 
Scale of control 5.0 (2.6) 4.0 (3.0-8.0)   6.0 (1.5) 6.0 (4.5-7.0) 0.3755 
        
Do you take allopurinol? 
   No (n=12)  Yes (n=12) p-value 
   Mean (SD) Median (IQR)   Mean (SD) Median (IQR) 
MCS 41.5 (10.7) 42.3 (34.8-50.3)  44.1 (12.2) 42.7 (36.7-54.0) 0.6033 
PCS 44 (8.9) 43.6 (35.7-51.7)  48.3 (8.0) 47.7 (43.2-53.1) 0.2481 
Weight 1.48 (0.54) 1.50 (1.44-1.75)  1.25 (1.23) 0.81 (0.31-2.13) 0.2826 
Appearance 1.42 (0.86) 1.30 (0.75-2.20)  1.33 (1.09) 1.25 (0.40-2.20) 0.8397 
Attribution 1.78 (0.89) 1.80 (1.10-2.30)  1.72 (0.99) 1.80 (0.90-2.40) 0.8847 
Scale of control 5.0 (1.5) 4.0 ( 4.0-7.0)   6.67 (1.4) 3.0 (2.0-4.5) 0.0155 
 
Do you take Glycosade™? 
   No (n=18)  Yes (n=6) p-value 
   Mean (SD) Median (IQR)   Mean (SD) Median (IQR) 
MCS 42.2 (11.1) 42.9 (35.9-51.9)  44.6 (12.7) 48.6 (34.7-50.4) 0.6892 
PCS 46 (9.3) 46.1 (41.9-52.8)  46.5 (6.7) 47.7 (41.9-50.2) 0.9734 
Weight 1.44 (0.96) 1.50 (0.88-1.8)  1.15 (0.89) 1.25 (0.38-1.75) 0.7885 
Appearance 1.41 (0.98) 1.25 (0.70-2.30)  1.28 (1.01) 1.30 (0.40-1.80) 0.8413 
Attribution 1.81 (0.98) 1.90 (1.00-2.40  1.57 (0.79) 1.60 (1.00-2.20) 0.6155 
Scale of control 5.8 (1.78) 6.0 (4.0-8.0)   6.0 (1.26) 6.5 (5.0-7.0) 0.858 
        
 
DISCUSSION 
This study aimed to provide more information about quality of life and body image in 
individuals with glycogen storage disease type Ia and also to examine the role that various factors of 
metabolic control play in these measures. Results found that quality of life and body image are both 
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impaired in adult patients with GSDIa and have provided preliminary data on factors that could 
influence this relationship. 
Previous studies have examined quality of life in patients with glycogen storage disease type 
I. An Italian multisite study performed by Sechi et al. in 2014 found that patients with GSD type I 
reported lower scores on general health perception and social functions and better scores in bodily 
pain and mental health in comparison to previously published normal control values for the measure 
(Sechi et al., 2014).  However, unlike the current study, they did not find any statistically significant 
differences in comparison to US norms for the physical and mental composite scores. Reasons for this 
difference include that perhaps Italian patients with GSDI have better quality of life than individuals 
in the US, or it could reflect an overall higher baseline quality of life in Italian individuals in the 
general population unrelated to having GSD. Overall, our data supports the general conclusions from 
Sechi et al. that adult patients with GSD report lower quality of life than the general population and 
also increases the generalizability of these findings, given that the original study included only Italian 
individuals. 
Flanagan et al. examined eating disorder symptoms, eating attitudes, and body esteem using 
validated questionnaires and interviews in a previous study on body image in patients with all 
subtypes of GSD. They reported body esteem scores in children and adults lower than the population 
norm (Flanagan et al., 2015). When looking at specific subscales however, only Attribution was 
statistically significant, while in the current study participants reported significantly lower scores on 
all subscales. Therefore, our data similarly confirms their results that adult patients with GSD have 
lower levels of body esteem than the general population. 
To the best of our knowledge this was the first study to examine why individuals with GSDIa 
have low quality of life and body image. Measures relating to demographics and metabolic control 
were evaluated to determine the nature of their relationship to outcome measures. For demographic 
factors, only gender was found to play a role. Females, in general, reported lower self-perceived 
control than males; however, this result was not statistically significant. Previous studies of the 
 20 
general population have found that women self-report lower physical and mental health status than 
men (Bertakis et al, 2000). Our data seems to support this trend in the GSD population as well. 
In reference to factors of metabolic control, individuals who use g-tubes had generally lower 
scores on the Attribution subscale of the BES. External devices have been shown to impact body 
image due to visibility of the device (Bolton, Lobben, & Stern, 2010). Therefore, these individuals 
could feel as though others are judging them for the g-tube, thereby lowering their body esteem. Of 
note, this trend was not significant, and only 2 individuals reported using g-tubes and therefore this 
data should be interpreted with caution. Additionally, taking Glycosade™ was not found to impact 
QoL and body image, which supports results of previous studies that have found that Glycosade™ 
does not impact QoL (Correia et al, 2008; Rousseau-Nepton et al, 2018).  
Complications reported were also found to be a significant factor in QoL and body image. 
They were found at similar levels to what has previously been reported in individuals with glycogen 
storage disease as adults (Talente et al., 1994). As expected, almost every listed complication was 
significantly associated with overall number of complications reported. However, this statistical 
significance was not reached for high cholesterol/triglycerides. This association may not have been 
seen due to the large number of individuals with high cholesterol in the general population. 
Interestingly, high cholesterol has been previously linked with obesity and high BMI in the general 
population, however this relationship was not found in our sample (Mokdad et al., 2003). In terms of 
the role these complications may play in body esteem and quality of life, having low blood sugars at 
least once a week every week and having kidney stones/kidney problems were both found to be 
significant in their role in body esteem. Particularly, individuals who reported having either 
complication were found to have statistically significantly poorer scores on the Attribution subscale 
of the BES, suggesting these complications may play a role in QoL and body image. 
Overall, while significant associations were found that influence perceived level of control, 
QoL, and body image in patients with GSDIa, there were no individual factors seen to strongly drive 
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the low QoL and body image in this population. Therefore, the relationship between factors of 
metabolic control and QoL and body image is most likely complex.  
Results of the study also highlight the difference in objective and subjective measures of 
metabolic control. For example, individuals taking allopurinol, an objective sign of poor control, 
reported better self-perceived control than those who did not. Taking medication may be influencing 
perceived control or symptom relief, with a consequent sense of well-being. Studies on other chronic 
conditions have seen medical adherence related to higher perceived control, as well (Broadbent, 
Donkin, & Stroh, 2011). From this, one could recommend increased focus on medical adherence due 
to the relationship between taking allopurinol and perception of control. The importance of subjective 
experience in various avenues is well-characterized. Subjective perceptions have been shown to have 
more of an effect on predicting disordered eating than objective measures of weight (Wilson, Tripp, 
& Boland, 2005). Additionally, subjective experience has been shown to be an important factor in 
QoL in the general population (Diener & Suh, 1997). It is important to recognize that while 
individuals may have objectively poorer metabolic control, their subjective control may be high, 
allowing them to have higher QoL and body image than what would be expected based solely on 
objective measures.  
Current guidelines for management of GSD type I include care by a team aware of the 
psychosocial considerations of the condition and discuss referral to a social worker or similar 
specialist if issues become apparent (Kishnani et al, 2014; Rake et al, 2002). This study supports 
results from previous studies finding that patients with GSDIa have lower quality of life and body 
image than the general population. It is then important for guidelines to address this subject in future 
management guidelines in more detail. There also likely exists a complex relationship in the 
development of low quality of life and body image in these patients. Therefore, targeted intervention 
to address concerns regarding body image and QoL would not be helpful and should instead be 
offered for all patients. Additionally, results of the study highlight the importance of objective versus 
subjective control and that objective control should not be the sole factor in determining individuals at 
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risk for issues related to QoL and body image. Future research should be performed evaluating 
accuracy in perception of metabolic control and the weight of objective versus subjective control in 
outcomes for these individuals. Additional research should also examine these findings in the context 
of a larger sample and for other subtypes of GSD, as complications of each differ (Chen & Weinstein, 
2016).  Overall, while psychosocial concerns may become apparent in childhood and adolescence in 
these patients, it is necessary to bring awareness to the fact that adult patients also report difficulty 
with body image and quality of life and therefore management in this context should be present 
throughout the lifetime.  
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